Oncolytics Biotech Inc ONCY

Takeda acquiring Nimbus Therapeutics subsid for US$4 Billion

[Noteable]

December 13, 2022 -  Takeda is paying $4 billion upfront to buy Nimbus’ wholly owned subsidiary, Nimbus Lakshmi, to obtain NDI-034858, a TYK2 inhibitor to be applied in psoriasis. TYK2 is part of the JAK family.

"By persuading Takeda that NDI-034858 can come from behind to make a dent on the market, Nimbus has continued a winning streak and business model that has allowed it to offload drug candidates while keeping its discovery engine in a high gear." 

https://www.fiercebiotech.com/biotech/takeda-bets-4b-upfront-nimbus-phase-3-ready-prospect-challenge-bristol-myers-psoriasis

[Noteable]

US$4 Billion for one drug in one indication ..... psoriasis .......  Whereas ONCY's pelareorep is an immune molecule platform technology that can be used in multiple high value cancer indications with multiple other I/O cancer drug treatments, the includes PD-(L)1 immune checkpoint inhibitors, CAR-T therapy, bispecifics and small molecules such as PARP and CDK4,6 inhbitors, for example.&

[Noteable]

That is ... US$4 Billion for one Phase 2 drug (phase 3 ready) in one indication........ Meanwhile ONCY' pelareorep is also a "Phase 3 ready" drug that is can potentially achieve "breakthrough" designation and an accelerated approval status that would result in immediate marketing approval followed-up with a post-marketing confirmatory trial for final FDA/EMA approval.&

[Noteable]

Again that is ... US$4 Billion for one Phase 2 drug (phase 3 ready) in one indication........ Meanwhile ONCY' pelareorep is also a "Phase 3 ready" drug that is can potentially achieve "breakthrough" designation and an accelerated approval status that would result in immediate marketing approval followed-up with a post-marketing confirmatory trial for

[Noteable]

Yesterday Nimbus Lakshimi (a subsidiary of Nimbus LLC.) was valued at $ "0" (zero)  ... and today it was acquired by Japan's Takeda for US$ 4 Billion in cash + US$2 Billion in commercial milestones for a total of US$6 Billion. https://www.businesswire.com/news/home/20221213005462/en/Takeda-to-Acquire-Nimbus-Therapeutics%E2%80%99-Highly-Selective-Allosteric-TYK2-Inhibitor-to

[fox7mf]

Crazy money...for psoriasis. For all the groundbreaking potential in cancer that Oncy's Pela has, well, how's about $8b in cash and $4b in commercial milestones totalling $12b usd? How does that sound Roche?

[Noteable]

An full acquisition of an independent company does not include commercial milestones. All of the deal value is cash up-front. Nimbus Lakshimi was a subsidiary of Nimbus Therapeutics and therefore commercial milestones could be part of the deal.

[Buckhenry]

the only folks that are in the know... as to whether any negotiations going on ain't talking... and if they are they will go the way of martha Stuart. 

[Noteable]

Yesterday Nimbus Lakshimi (a subsidiary of Nimbus LLC.) was valued at $ "0" (zero)  ... and today it was acquired by Japan's Takeda for US$ 4 Billion in cash + US$2 Billion in commercial milestones for a total of US$6 Billion. So if Nimbus Lakshimi went from $US 0.00 to US$6.0 Billion (all-in one day) then ONCY's immune molecule platform

[Noteable]

Contrary to what some simple minded detractors try to say, Nimbus Lakshimi employed 18 people and was considerably smaller than ONCY in staffing and spend complement. Yet Nimbus Lakshimi's worth rose from US $0.00 to US $6.0 Billion in 1 day through Takada's acquisition. https://www.buzzfile.com/business/Nimbus-857-999-2009

[Noteable]

Business Description Nimbus Lakshmi, which also operates under the name Nimbus, is located in Cambridge, Massachusetts. This organization primarily operates in the Druggists' Preparations (Pharmaceuticals) business / industry within the Chemicals and Allied Products sector. This organization has been operating for approximately 12 years. Nimbus Lakshmi is estimated to generate $1.2

[Noteable]

At the beginning of the week Nimbus Lakshimi was valued at US$ 0.00. Yesterday Nimbus Lakshimi was acquired for a total of US$6.0 Billion that included US$4 Billion in cash upfront.

[Quentin30]

You can use Pela with coconut milk too Noteable, but to administer it to patients and make money from sales, you do realise you need a marketing authorisation, you do realise that right ? So, for all the combos you mention, all of which will require (for US at least) two randomised trials... WHO will be paying for all that..? It seems all ONCY ever does is start yet more trials, never quite

[Noteable]

Last week Nimbus Lakshimi was valued at US$ 0.00. Then out of nowhere, Japan's Takeda announced that Takeda was acquiring Nimbus Lakshimi for a total of US$6.0 Billion that included US$4 Billion in cash upfront. Deals happen fast

[Noteable]

Nimbus Lakshimi (a subsidiary of Nimbus LLC.) was valued at $ "0" (zero)  ... and was acquired by Japan's Takeda for US$ 4 Billion in cash + US$2 Billion in commercial milestones  for a total of US$6 Billion. https://www.buzzfile.com/business/Nimbus-857-999-2009  Furthermore, Nimbus Lakshimi had NO institutional investors.

[Noteable]

Posted in December 2022 -  Takeda acquired Nimbus Therapeutics for US$4 Billion for one drug in one indication ..... psoriasis .......  Whereas ONCY's pelareorep is an immune molecule platform technology that can be used in multiple high value cancer indications with multiple other I/O cancer drug treatments, the includes PD-(L)1 immune checkpoint inhibitors, CAR-T therapy

[Noteable]

Takeda announced it had completed an acquisition of all shares of Nimbus Lakshmi, Inc. (“Lakshmi”) from Nimbus Therapeutics, LLC (“Nimbus”), on February 8, 2023 (EST). The agreement closed for US$6 Billion. Under the terms of the agreement and following the closing of the transaction, Takeda will pay Nimbus approximately 4 billion USD upfront, after adjusting items including closing indebtedness